Subject(s)
Confidentiality/legislation & jurisprudence , Reproductive Techniques, Assisted/legislation & jurisprudence , Tissue and Organ Procurement/legislation & jurisprudence , Confidentiality/ethics , Female , France , Humans , Male , Oocyte Donation/legislation & jurisprudence , Pedigree , SpermatozoaABSTRACT
OBJECTIVE: To compare the effectiveness of two intensified insulin regimens, i.e., pump delivery versus multiple daily injections in patients with type 2 diabetes not optimally controlled with conventional insulin therapy. RESEARCH DESIGN AND METHODS: Seventeen type 2 diabetes patients uncontrolled by two daily injections of regular plus NPH were randomly assigned in a cross-over fashion to either three daily injections of lispro plus NPH or pump device delivering lispro. HbA1c, 6 points capillary blood glucose, 24-hour continuous glucose monitoring system tracings and global satisfaction score were evaluated at the end of each 12-week treatment period. RESULTS: HbA1c decreased from 9.0+/-1.6% to 8.6+/-1.6% with multiple injections and 7.7+/-0.8% with pump device (p<0.03). Capillary blood glucose was lowered at all time-points with pump, but only at morning with multiple injections (p<0.01). Compared to conventional therapy, pump reduced hyperglycemic area under curve by 73% (p<0.01), but multiple injections by only 32% (p=0.08). Rate of hypoglycemia was not increased and patient's satisfaction was comparable with both intensive treatments. CONCLUSIONS: Pump therapy provides a better metabolic control than injection regimens, and seems to be safe and convenient in patients with type 2 diabetes who fail to respond to conventional insulin therapy.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Insulin/analogs & derivatives , Administration, Cutaneous , Area Under Curve , Blood Glucose/analysis , Drug Administration Schedule , Female , Glycated Hemoglobin , Hemoglobins/metabolism , Humans , Injections, Subcutaneous , Insulin/administration & dosage , Insulin/pharmacology , Insulin/therapeutic use , Insulin Infusion Systems , Insulin Lispro , Male , Middle Aged , Monitoring, Physiologic , Patient Satisfaction , Surveys and Questionnaires , Treatment FailureABSTRACT
We report the unusual occurrence of a neuroendocrine prostatic tumor in two young males with multiple endocrine neoplasia (MEN) 2B. Immunohistochemistry of the tumor markers may help differentiate a primary neuroendocrine prostate tumor from the metastasis of a medullary thyroid carcinoma of poor prognosis. MEN 2B hallmarks (i.e. plasma thyrocalcitonin and urinary metanephrines) may be systematically investigated in neuroendocrine tumors of the prostate, and conversely prostate examination may be performed in the periodic screening of MEN 2B male patients.
